The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

Novo Nordisk A/S’s earnings rose less than expected in the second quarter as the Danish drugmaker contends with competition ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...